These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy. Lee BH; Waldrop MA; Connolly AM; Ciafaloni E Muscle Nerve; 2021 Aug; 64(2):153-155. PubMed ID: 33959970 [TBL] [Abstract][Full Text] [Related]
8. Evolving approaches to prenatal genetic counseling for Spinal Muscular Atrophy in the new treatment era. Zettler B; Estrella E; Liaquat K; Lichten L J Genet Couns; 2022 Jun; 31(3):803-814. PubMed ID: 35037741 [TBL] [Abstract][Full Text] [Related]
9. Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study. Bitetti I; Lanzara V; Margiotta G; Varone A Gene Ther; 2023 Aug; 30(7-8):592-597. PubMed ID: 35606491 [TBL] [Abstract][Full Text] [Related]
10. [Spinal muscular atrophy]. Martin P; Horber V; Park J; Kronlage C; Grimm A Nervenarzt; 2022 Feb; 93(2):191-200. PubMed ID: 35037967 [TBL] [Abstract][Full Text] [Related]
11. Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go. Dangouloff T; Vrščaj E; Servais L; Osredkar D; Neuromuscul Disord; 2021 Jun; 31(6):574-582. PubMed ID: 33985857 [TBL] [Abstract][Full Text] [Related]
12. Spinal Muscular Atrophy: An Evolving Scenario through New Perspectives in Diagnosis and Advances in Therapies. Angilletta I; Ferrante R; Giansante R; Lombardi L; Babore A; Dell'Elice A; Alessandrelli E; Notarangelo S; Ranaudo M; Palmarini C; De Laurenzi V; Stuppia L; Rossi C Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834320 [TBL] [Abstract][Full Text] [Related]
13. Gene transfer therapy in children with spinal muscular atrophy: A single-center experience with a cohort of 25 children. Chencheri N; Alexander G; Nugud A; Majadas E; Salim H; Prudhomme K; DeJager N; Janardhanan VS; Elbashir H Muscle Nerve; 2023 Sep; 68(3):269-277. PubMed ID: 37392188 [TBL] [Abstract][Full Text] [Related]
14. How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison. Ribero VA; Daigl M; Martí Y; Gorni K; Evans R; Scott DA; Mahajan A; Abrams KR; Hawkins N J Comp Eff Res; 2022 Apr; 11(5):347-370. PubMed ID: 35040693 [No Abstract] [Full Text] [Related]
15. Nusinersen treatment of spinal muscular atrophy - a systematic review. Albrechtsen SS; Born AP; Boesen MS Dan Med J; 2020 Aug; 67(9):. PubMed ID: 32800069 [TBL] [Abstract][Full Text] [Related]
17. Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence. Hjartarson HT; Nathorst-Böös K; Sejersen T Drug Des Devel Ther; 2022; 16():1865-1883. PubMed ID: 35734367 [TBL] [Abstract][Full Text] [Related]
18. Bridging the Gap: Gene Therapy in a Patient With Spinal Muscular Atrophy Type 1. Costamagna G; Govoni A; Wise A; Corti S Neurology; 2022 Nov; 99(21):952-956. PubMed ID: 36319109 [TBL] [Abstract][Full Text] [Related]
19. Real-Life Outcome After Gene Replacement Therapy for Spinal Muscular Atrophy: A Multicenter Experience. Tokatly Latzer I; Sagi L; Lavi R; Aharoni S; Bistritzer J; Noyman I; Ginsburg M; Lev-Or A; Katzenellenbogen S; Nevo Y; Fattal-Valevski A Pediatr Neurol; 2023 Jul; 144():60-68. PubMed ID: 37149951 [TBL] [Abstract][Full Text] [Related]
20. The respiratory impact of novel therapies for spinal muscular atrophy. Paul GR; Gushue C; Kotha K; Shell R Pediatr Pulmonol; 2021 Apr; 56(4):721-728. PubMed ID: 33098622 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]